NYMC Faculty Publications
FDY-5301: An Innovative Approach to the Treatment of Revascularization Coronary Injury
Author Type(s)
Faculty
DOI
10.1097/CRD.0000000000000517
Journal Title
Cardiology in Review
First Page
429
Last Page
432
Document Type
Article
Publication Date
9-1-2024
Department
Medicine
Abstract
After experiencing an acute ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) is a preferred method of restoring blood flow to the heart. While this reperfusion has long-term benefits, it can result in reperfusion injury in the short term, which involves the formation of reactive oxygen species (ROS) and neutrophil recruitment. FDY-5301 is a sodium iodide-based drug that acts as a catalyst in the conversion of hydrogen peroxide to water and oxygen. FDY-5301 is designed to be administered as an intravenous bolus following a STEMI, before reperfusion with PCI, to reduce the damage associated with reperfusion injury. Clinical trials have shown FDY-5301 administration to be safe, feasible, and fast-acting in its ability to increase plasma iodide concentration, and the results are favorable in demonstrating potential efficacy. FDY-5301 shows potential in its use to reduce the effects of reperfusion injury, and ongoing Phase 3 trials will allow for continued evaluation of its performance.
Recommended Citation
Williams, L. E., & Frishman, W. H. (2024). FDY-5301: An Innovative Approach to the Treatment of Revascularization Coronary Injury. Cardiology in Review, 32 (5), 429-432. https://doi.org/10.1097/CRD.0000000000000517